213 related articles for article (PubMed ID: 31509517)
1. Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists.
Wang CY; Lin YS; Wang YH; Lai CC; Wang HC; Chen L; Yu CJ;
Aging (Albany NY); 2019 Sep; 11(17):6863-6871. PubMed ID: 31509517
[TBL] [Abstract][Full Text] [Related]
2. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
[TBL] [Abstract][Full Text] [Related]
3. Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids.
Huang TM; Kuo KC; Wang YH; Wang CY; Lai CC; Wang HC; Chen L; Yu CJ;
BMC Infect Dis; 2020 Sep; 20(1):706. PubMed ID: 32977747
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
Perrone V; Sangiorgi D; Buda S; Degli Esposti L
Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
[TBL] [Abstract][Full Text] [Related]
5. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
6. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
[TBL] [Abstract][Full Text] [Related]
7. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS).
Janson C; Larsson K; Lisspers KH; Ställberg B; Stratelis G; Goike H; Jörgensen L; Johansson G
BMJ; 2013 May; 346():f3306. PubMed ID: 23719639
[TBL] [Abstract][Full Text] [Related]
8. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
[TBL] [Abstract][Full Text] [Related]
9. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Frois C; Wu EQ; Ray S; Colice GL
Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
[TBL] [Abstract][Full Text] [Related]
10. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
Solidoro P; Patrucco F; Bagnasco D
Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
[No Abstract] [Full Text] [Related]
11. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study.
Wang CY; Lai CC; Yang WC; Lin CC; Chen L; Wang HC; Yu CJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2775-2783. PubMed ID: 27877031
[TBL] [Abstract][Full Text] [Related]
12. Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD.
Muiser S; Imkamp K; Seigers D; Halbersma NJ; Vonk JM; Luijk BHD; Braunstahl GJ; van den Berg JW; Kroesen BJ; Kocks JWH; Heijink IH; Reddel HK; Kerstjens HAM; van den Berge M
Thorax; 2023 May; 78(5):451-458. PubMed ID: 36725331
[TBL] [Abstract][Full Text] [Related]
13. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
14. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Nannini L; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2003; (4):CD003794. PubMed ID: 14583994
[TBL] [Abstract][Full Text] [Related]
15. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Nannini L; Cates CJ; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2004; (3):CD003794. PubMed ID: 15266502
[TBL] [Abstract][Full Text] [Related]
16. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis.
Tricco AC; Strifler L; Veroniki AA; Yazdi F; Khan PA; Scott A; Ng C; Antony J; Mrklas K; D'Souza J; Cardoso R; Straus SE
BMJ Open; 2015 Oct; 5(10):e009183. PubMed ID: 26503392
[TBL] [Abstract][Full Text] [Related]
17. Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety.
Suissa S; Dell'Aniello S; Ernst P
Respir Med; 2021; 189():106645. PubMed ID: 34757243
[TBL] [Abstract][Full Text] [Related]
18. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Evans DJ; Karner C; Cates CJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
[TBL] [Abstract][Full Text] [Related]
19. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
20. Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment.
Davis JR; Kern DM; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
J Manag Care Spec Pharm; 2016 Mar; 22(3):293-304. PubMed ID: 27003559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
